GH Research Q3 net loss narrows as costs fall

By Reuters News


Overview

  • Biopharma firm's Q3 net loss narrowed yr/yr as R&D and G&A expenses declined

  • Company ended Q3 with $350.6 mln in cash, cash equivalents and marketable securities

  • Company received positive initial FDA feedback on pivotal TRD program, expects End-of-Phase 2 meeting in Q1 2027


Outlook

  • GH Research expects End-of-Phase 2 FDA meeting for TRD program in Q1 2027

  • Company plans to initiate TRD pivotal program shortly after FDA meeting, pending alignment

  • GH Research targets PPD pivotal program initiation in H2 2027, subject to regulatory alignment


Result Drivers

  • LOWER R&D EXPENSES - Co said Q3 research and development expenses fell due to decreased technical and clinical development costs

  • LOWER G&A EXPENSES - Co said Q3 general and administrative expenses declined due to lower professional fees


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

$0.18


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for GH Research PLC is $39.50, about 113.6% above its November 12 closing price of $18.49


Reuters Recommended Reads

  • Nov 12 - Fractyl Health's Q3 net loss narrows as costs fall, shifts focus to Revita

  • Nov 12 - Rocket Pharmaceuticals Q3 net loss narrows as R&D costs fall

  • Nov 12 - Prime Medicine Q3 loss narrows as expenses decline


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk